arrow
S

Stanley R. Riddell

university of washington
H指数:111
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination

通过亲和力组合平衡嵌合抗原受体T细胞疗法的有效性与安全性

2026-04-100
OA
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials

Gamma-分泌酶抑制剂对BCMA CAR-T疗法后多发性骨髓瘤结局的影响:两项I期试验的比较

2025-09-080
PRE
Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy

设计用于癌症治疗的敏感型单特异性及双特异性合成嵌合T细胞受体

2025-03-170
OA
Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion

组蛋白标记识别解析car-t起源子集,临床潜力和扩展的新型转录因子

2024-09-270
OAAI
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target (vol 132, e157101, 2022)
2024-08-150
OAAI
TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
2024-04-194
OA
Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks
IMMUNITY
IF26.3
2024-02-013
OA
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

anti-PD-L1抗体起始时间影响CD19 car-t细胞治疗大b细胞淋巴瘤的疗效/毒性

2024-01-2311
OAAI
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

与CD19 CAR T细胞治疗复发/难治性CLL的长期结果相关的因素

2023-11-177
OAAI
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target
2022-11-1522
OAAI